New study suggests genetic testing could be appropriate for all motor neuron disease (MND) patients whether or not they have a family history of the disease
Research from the Sheffield Institute for Translational Neuroscience (SITraN) suggests that routine genetic testing may be appropriate for all MND patients and could impact disease subclassification and clinical care.
New partnership to develop drug targets for the treatment of Parkinson’s disease
Our researchers are collaborating with Verge Genomics to accelerate the validation of novel drug targets and the screening of new drug compounds for the treatment of Parkinson’s disease.
Researchers find different processes to protect the genome are needed throughout the lifecourse
A new study published in Science Advances investigates Tdp1, a protein involved in DNA repair and its protective effect against damage caused by topoisomerase; an enzyme that participates in the over and underwinding of DNA.